News Feature
First randomized, double-blind, placebo controlled study to show telomeres getting longer in humans

First randomized, double-blind, placebo controlled study to show telomeres getting longer in humans

By


Salvador L, Singaravelu G, Harley CB, Flom P, Suram A, Raffaele JM.

TA-65 is a dietary supplement based on an improved formulation of a small molecule telomerase activator that was discovered in a systematic screening of natural product extracts from traditional Chinese medicines. This study summarizes the findings on telomere length (TL) changes from a randomized, double blind, placebo controlled study of TA-65 over a 1 year period. The study was conducted on 97 relatively healthy cytomegalovirus-positive subjects aged 53-87 years old. Subjects taking the low dose of TA-65 (250 U) significantly increased TL over the 12 months period, as compared to the placebo group (530 ± 180 bp; p = 0.005), whereas subjects in the placebo group significantly lost TL (290 ± 100 bp; p = 0.01). The high dose of TA-65 (1000 U) showed a trend of improvements in TL compared with that of the placebo group; however, the improvements did not reach statistical significance. TL changes in the low-dose group were similar for both median and 20th percentile TLs. The findings suggest that TA-65 can lengthen telomeres in a statistically and possibly clinically significant manner.

Study Summary

  • Study participants: 97 men and women (53-87 years old)

  • Study length: 12 months

  • First study to show statistically significant (p<0.005) lengthening of telomeres in humans:


    As expected, the placebo group showed a decrease in telomere length

    Placebo Group
    Decrease in median telomere length over 12 months

    Median telomere length 290 ± 100 bp
    20th percentile telomere length 170 ± 50 bp

    While the group taking one capsule of TA-65® (250 Units) per day showed an increase in telomere length

    TA-65® Group
    Increase vs placebo group in median telomere length over 12 months

    Median telomere length 533 ± 180 bp
    20th percentile telomere length 270 ± 90 bp
  • Published in Rejuvenation Research, a PubMed-indexed and peer-reviewed journal
    [PMID: 26950204]



RELATED NEWS STORIES
TA-65, A Telomerase Activator, Improves Cardiovascular Markers in Patients with Metabolic Syndrome
Telomerase Activator Improves Cardiovascular Markers in Metabolic Syndrome Patients
New Study Observes the Impact of Telomerase Activation on Metabolic and Cardiovascular Health Markers
Functional Assessment of Pharmacological Telomerase Activators in Human T Cells
CONNECT WITH T.A. SCIENCES
Toll-Free: 888.360.8886